Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share from the same period last year.
Neurocrine Biosciences Presents Data At MDS International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Comparable Improvement Over Time In Tardive Dyskinesia Severity And Impact Following Treatment With INGREZZA Capsules
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today presented findings from a data analysis of KINECT®-4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia (TD)
